Current Report Filing (8-k)
December 13 2016 - 1:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 9th, 2016
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
000-52403
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
(Address of principal executive offices and
Zip Code)
(877) 424-2429
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a -12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d -2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02 – DEPARTURE OF DIRECTORS
OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On December
9th, 2016,
Mr. Dov Weinberg resigned his position as Chief Financial Officer of the Corporation. This decision was not the
result of any disagreement with the Company.
On the same day the Company appointed Mr. Uri
Ben-Or as Chief Financial Officer of the Corporation. Mr. Ben-Or, 46, has over 20 years of broad experience in corporate finance,
accounting, M&A transactions, IPO's and operations.
Mr. Ben-Or is CEO & Founder of one of the
few financial firms in Israel to have the International Standard on Assurance Engagement (ISAE 3402/SAS 70 Type II) assurance
with control compliances, the new global standard for assurance reporting. He previously served as an Auditor at PricewaterhouseCoopers
Accounting Firm.
Mr. Ben-Or holds a BA degree in Business from
the College of Administration, an MBA degree from the Bar Ilan University and is a Certified Public Accountant.
ITEM 9.01 FINANICAL STATEMENTS & EXHIBITS
(d) Exhibits
|
99.1
|
Resignation of Mr. Weinberg
|
|
99.2
|
Board of Director Resolution naming Uri Ben-Or as CFO
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 13, 2016
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
|
|
By:
/s/ Itamar Borochov
|
|
Itamar Borochov, Director, CEO
|
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Apr 2023 to Apr 2024